Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.

MLA

Satoshi Kawano, et al. “Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.” PLoS ONE, vol. 12, no. 1, Jan. 2017, p. e0170539. EBSCOhost, https://doi.org/10.1371/journal.pone.0170539.

APA

Satoshi Kawano, Alexandra R Grassian, Masumi Tsuda, Sarah K Knutson, Natalie M Warholic, Galina Kuznetsov, Shanqin Xu, Yonghong Xiao, Roy M Pollock, Jesse J Smith, Kevin W Kuntz, Scott Ribich, Yukinori Minoshima, Junji Matsui, Robert A Copeland, Shinya Tanaka, & Heike Keilhack. (2017). Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma. PLoS ONE, 12(1), e0170539. https://doi.org/10.1371/journal.pone.0170539

Chicago

Satoshi Kawano, Alexandra R Grassian, Masumi Tsuda, Sarah K Knutson, Natalie M Warholic, Galina Kuznetsov, Shanqin Xu, et al. 2017. “Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.” PLoS ONE 12 (1): e0170539. doi:10.1371/journal.pone.0170539.